• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Synthetic Biologics Inc.

    10/17/23 6:05:12 AM ET
    $SYN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SYN alert in real time by email
    Inline XBRL Viewer
    • Menu Menu
      Information Save XBRL Instance Save XBRL Zip File Open as HTML Settings Help
    • Sections Sections
    • Reference Options
    • Data Data
    • Tags Tags
    • More Filters More Filters
      Periods
      Measures
      Axis
      Members
      Scale
      Balance 2
    • Reset All Filters
    • Links
    • Facts

    Loading Inline Form.

    Tagged Sections

    Help

    The Inline XBRL viewer allows a user to quickly and easily review details of the tagged information in an Inline document by automatically placing a top and bottom highlight border around each tagged numeric fact and left and right border for each block tagged fact. Hovering over a tagged fact will highlight (shade) all content related to the tagged fact, and clicking on a tagged fact will reveal its tagging details in the Fact Review Window. Navigation, search and filter options are also provided to easily refine and identify specific types of tagged information.

    The Fact Review Window shows the tagging details for the currently selected fact, which is highlighted with a solid blue border. There are four categories of fact detail which can be viewed; an "N/A" value indicates there is no available information for the item within the given category:

    • Attributes - All primary information (as applicable) describing the tagged fact including period, sign, decimals, dimensional detail (axes and members), scale, measure and data type.
    • Labels - Detailed documentation (definition) for the tag used, and other labels.
    • References - Authoritative reference information (as applicable) for the selected tag.
    • Calculation - Balance and calculation hierarchy details (numeric non-dimensioned items only).

    There are two ways to search the document: FACTS AND SECTIONS. To search information, enter a keyword in a search box and select the magnifying glass icon to return matching results. Search operators "and" (via "AND" or "&") and "or" (via "OR" or "|") are available to further refine a search.

    FACTS

    The Search Facts box can be used to find tagged facts matching entered keywords. By default, tag name, tag labels, and tagged content are included in Search. Tagged facts matching the search criteria are shown with a yellow-colored (default) shading on the page and appear in the Facts List. Select the "X" button to the left of the magnifying glass icon to clear the search.

    The content included in Search can be increased to included tag definitions, dimensions, and authoritative references by selecting the cog / wheel icon to the left of the search box. See Settings for more information.

    SECTIONS

    The Search Sections box can be used to filter the tagged sections of the financial statements.

    Filters change the number of highlighted facts and items in the fact list by providing several ways to review and pinpoint certain tagged information. Multiple filters can be used at once.

    DATA FILTERS

    These filter options allow the user to refine the highlighted tagged facts by data type:

    • All - Displays all tagged data (default)
    • Amounts Only - Numeric facts only
    • Text Only - Textual facts only
    • Calculations Only - Numeric facts participating in a calculation only
    • Negatives Only - Negative Numeric amounts only
    • Additional Items Only - Tagged facts without a corresponding HTML presentation (i.e., hidden facts) only

    TAGS FILTER

    These filters allow the user to refine the highlighted facts by tag type:

    • All - Displays all tagged data (default)
    • Standard Only- Facts with standard tags from a common taxonomy (e.g., US_GAAP, IFRS, DEI).
    • Custom Only - Facts with extension "custom" tags unique to the entity's document.

    MORE FILTERS

    Additional filters that allow user to further refine the highlighted facts:

    • Periods - List of all used context years and reporting periods
    • Measures - List of all used units of measure (e.g., US Dollars); as applicable
    • Axis - List of all used axis (dimensions); as applicable (dimensions); as applicable
    • Scale - List of all used scaled options (e.g., thousands, millions); as applicable
    • Balance - Debit, credit; as applicable

    Multiple filters work in conjunction with each other. For example, selecting the "Amounts Only" Data filter and "Custom Only" Tags filter will highlight only numeric tagged facts using custom tags and list them in the fact list. Active filters are displayed in the Filter toolbar as they are selected. Active filters can be removed individually by unchecking or selecting ALL option for each filter, or all at once via the "Reset All Filters" option.

    On the toolbar, select the "count" to the right of the word Facts (e.g., Facts 234) to reveal the Facts List results - a navigable listing of all currently highlighted tagged facts. The count represents the current number of facts.

    By default, all tagged facts are displayed in the Fact List Results. The list content and count reflects the currently highlighted facts (i.e., both Filters and Search criteria refine the list to match the highlighted tagged facts). Navigation controls are available to move through the list as well as move the current view to the corresponding highlighted fact location automatically. When a fact in the Facts Results List is selected, it will reveal the Fact Review Window.

    Certain letters may appear to the right of an item in the Fact Result list to indicate a certain property. If the letter "A" appears for a fact, it indicates the fact is additional data (i.e., hidden with potentially no corresponding HTML presentation). If the letter "C" appears, the fact is tagged with a custom tag. If the letter "D" appears, the fact is tagged with dimensional information.

    The SECTIONS toolbar item provides a listing of the tagged sections of the Inline document. Sections are divided into three groups:

    • Document & Entity Information
    • Financial Statements
    • Notes to the Financial Statements

    By expanding a group and selecting a section item in the listing, Inline XBRL viewer will navigate to that section. When the Tagged Sections feature is open, the Search Sections box will additionally filter the list of sections to only those sections that match the entered criteria.

    Information

    The Information menu item provides additional detail about the current Inline document and customizable viewer settings.

    • Company and Document - Basic company and document information
    • Tags - Fact and tag (standard and custom) information
    • Files - Files used
    • Additional Items - Additional hidden data that's been tagged but potentially does not have a corresponding location in the HTML

    Save XBRL Instance

    The Save XBRL Instance menu item allows an XBRL instance document (*.xml) that is extracted from the Inline document to be saved locally for use by software supporting the XBRL format.

    Save XBRL Zip

    The Save XBRL Zip menu item allows a zip file (*.zip) that contains the as-provided XBRL instance document and related custom taxonomy files to be saved locally.

    Settings

    The Settings menu item provides the ability to customize Viewer features.

    Tagged Fact Hover

    • On - Displays the hover fact review window for any tagged fact*
    • Off - Hides the hover fact review window for any tagged fact (default)

    * May impact performance with certain web browsers.

    Auto Scrolling Position (This setting will have no effect on IE 10 or Safari)

    • Top - Selecting a fact from the Sections Menu or the Fact Menu will automatically scroll that element to the Top of the Inline XBRL viewer window (default)
    • Center - Selecting a fact from the Sections Menu or the Fact Menu will automatically scroll that element to the middle of the Inline XBRL viewer window

    Highlight Colors (Use the save and reset buttons to save the selected setting or reset to default)

    • Tagged Data - Change the highlight color of the tagged fact border
    • Search Results - Change the background color of tagged items matching the Search results
    • Selected Fact - Change the color of highlight border used to identify the currently selected fact
    • Tag Shading (hover) - Change the color of the shading applied to tagged data on hover

    Search Options

    • Match Case - Matches the specific case of the entered Search keyword
    • Include Labels - Extends Search to include tag labels
    • Include Definitions - Extends Search to include tag definitions
    • Include Dimensions - Extends Search to include dimensional detail
    • Include References - Extends Search to include authoritative reference information. Optionally specify the reference parts to include in the search (e.g., topic, subtopic, section)

    Help(this content)

    Version

    Indicates the current build of the Inline XBRL viewer application.

    Facts

    Settings

    Selecting a fact from the Sections Menu or the Fact Menu will automatically scroll that element to the (Top, or Middle) of the viewer window. This setting will have no use on IE 10, or Safari.





    Nested Facts /

    Get the next $SYN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SYN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SYN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Mason Capital Management Highlights Corporate Governance Failures and Significant Shareholder Value Destruction Under Grifols Board of Directors

      Sends Letter to Board Detailing Board's Conflicts of Interest and History of Poor Capital Allocation Expresses Urgent Need for Independent Directors and Proper Oversight to Unlock Value Believes Rumored Brookfield Transaction Substantially Undervalues Grifols Mason Capital Management LLC ("Mason"), a registered investment advisor to funds and accounts holding approximately 2.1% of Grifols S.A. ("Grifols" or the "Company") (BME: GRF) (NASDAQ:GRFS) class A shares, today sent a letter to the Grifols Board of Directors (the "Board"). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241107873955/en/Historical Forward EV/EBITDA Multip

      11/8/24 3:54:00 PM ET
      $GRFS
      $SYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synthetic Biologics Rebrands as Theriva Biologics

      ROCKVILLE, Md., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Theriva Biologics, Inc. (NYSE:TOVX), ("Theriva" or the "Company") is the new name of Synthetic Biologics, Inc. (NYSE:SYN). The new name, logo and branding elements were introduced to better reflect Theriva's position as a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet need. In addition, the Company announced its common stock is expected to begin trading on NYSE American under the new ticker symbol "TOVX" on Thursday, October 13, 2022. "The rebranding solidifies our strategic transformation and reflects our sharpened focus on advancing unique, oncoly

      10/12/22 8:00:00 AM ET
      $SYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synthetic Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

      - The DSMC has reviewed the safety and pharmacokinetic data from Cohort 1 and recommended that the study may proceed to enroll patients into Cohort 2 - ROCKVILLE, Md., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE:SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced a positive outcome from the Data and Safety Monitoring Committee (DSMC) review of results from the first Cohort of its Phase 1b/2a randomized, double-blinded, placebo-controlled clinical trial of SYN-004 (ribaxamase) in allogeneic hematopoietic cell transplant (HCT) recipients for the prevention of acute graft-versus-host

      9/27/22 8:00:00 AM ET
      $SYN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SYN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Synthetic Biologics Inc. (Amendment)

      SC 13G/A - Synthetic Biologics, Inc. (0000894158) (Subject)

      2/23/22 4:42:27 PM ET
      $SYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Synthetic Biologics Inc. (Amendment)

      SC 13G/A - Synthetic Biologics, Inc. (0000894158) (Subject)

      2/4/22 4:23:58 PM ET
      $SYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed

      SC 13D/A - Synthetic Biologics, Inc. (0000894158) (Subject)

      3/2/21 3:33:11 PM ET
      $SYN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SYN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Shallcross Steven A

      4 - Theriva Biologics, Inc. (0000894158) (Issuer)

      12/15/23 4:07:49 PM ET
      $SYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Wolf Jeffrey Alan

      4 - Theriva Biologics, Inc. (0000894158) (Issuer)

      12/15/23 4:01:42 PM ET
      $SYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Monahan John J

      4 - Theriva Biologics, Inc. (0000894158) (Issuer)

      12/15/23 4:00:19 PM ET
      $SYN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SYN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $SYN
    SEC Filings

    See more
    • Synthetic Biologics upgraded by Maxim Group

      Maxim Group upgraded Synthetic Biologics from Hold to Buy

      3/12/21 10:41:11 AM ET
      $SYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synthetic Biologics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Theriva Biologics, Inc. (0000894158) (Filer)

      2/7/24 8:10:24 AM ET
      $SYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synthetic Biologics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Theriva Biologics, Inc. (0000894158) (Filer)

      1/8/24 8:10:38 AM ET
      $SYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Synthetic Biologics Inc.

      10-Q - Theriva Biologics, Inc. (0000894158) (Filer)

      11/13/23 8:15:58 AM ET
      $SYN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SYN
    Financials

    Live finance-specific insights

    See more
    • Synthetic Biologics Reports Second Quarter 2022 Operational Highlights and Financial Results

      -Prioritizing the advancement of novel oncolytic adenovirus (OV) platform- -Cash balance as of August 1, 2022 of $53.5 million, including the additional $3 million in gross proceeds from convertible preferred financing extends funding for business operations into Q1 2024- -Conference call and webcast to be held today at 8:30 a.m. ET- ROCKVILLE, Md., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE:SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today reported financial results for the second quarter ended June 30, 2022, and provided a corporate update. "We are pleased with the steady progress th

      8/11/22 8:00:00 AM ET
      $SYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synthetic Biologics to Host Conference Call and Webcast to Discuss Second Quarter 2022 Operational Highlights and Financial Results

      ROCKVILLE, Md., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE:SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced that it plans to host a conference call on Thursday, August 11, 2022, at 8:30 a.m. ET to discuss its financial results for the quarter ended June 30, 2022 and provide a corporate update. Individuals may participate in the live call via telephone by dialing (800) 289-0571 (domestic) or (929) 477-0324 (international) and using the conference ID: 7145566. Participants are asked to dial in 15 minutes before the start of the call to register. Investors and the public can acces

      8/4/22 8:00:00 AM ET
      $SYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synthetic Biologics Reports First Quarter 2022 Operational Highlights and Financial Results

      -Encouraging data further supports the development of novel oncolytic adenovirus (OV) platform; Announced a peer-reviewed publication highlighting positive clinical data on VCN-01 and an upcoming oral presentation on VCN-11, a novel oncolytic adenovirus designed to evade neutralizing antibodies- - Reported positive safety data on SYN-020 intestinal alkaline phosphatase from the Phase 1 Multiple Ascending Dose clinical trial- -Formed Scientific Advisory Board and strengthened the leadership team to support transformative clinical development strategy and extension into oncology - -As of March 31, 2022, Synthetic Biologics reports $56.7 million in cash, which is expected to provide runway

      5/16/22 8:00:00 AM ET
      $SYN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SYN
    Leadership Updates

    Live Leadership Updates

    See more
    • Mason Capital Management Highlights Corporate Governance Failures and Significant Shareholder Value Destruction Under Grifols Board of Directors

      Sends Letter to Board Detailing Board's Conflicts of Interest and History of Poor Capital Allocation Expresses Urgent Need for Independent Directors and Proper Oversight to Unlock Value Believes Rumored Brookfield Transaction Substantially Undervalues Grifols Mason Capital Management LLC ("Mason"), a registered investment advisor to funds and accounts holding approximately 2.1% of Grifols S.A. ("Grifols" or the "Company") (BME: GRF) (NASDAQ:GRFS) class A shares, today sent a letter to the Grifols Board of Directors (the "Board"). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241107873955/en/Historical Forward EV/EBITDA Multip

      11/8/24 3:54:00 PM ET
      $GRFS
      $SYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synthetic Biologics Reports 2020 Year End Operational Highlights and Financial Results

      ROCKVILLE, Md., March 4, 2021 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, today provided a clinical programs update and reported financial results for the year ended December 31, 2020. Recent developments: Received Institutional Review Board ("IRB") approval from Washington University School of Medicine in St. Louis for the SYN-004 (ribaxamase) Phase 1b/2a clinical trial protocol in allogeneic hematopoietic cell transplant ("HCT") recipients Commenced screening of patients for enrollment of the f

      3/4/21 4:10:00 PM ET
      $SYN
      Biotechnology: Pharmaceutical Preparations
      Health Care